A randomized, double blind phase II proof-of-concept superiority trial of fosravuconazole 200 mg or 300 mg weekly dose versus itraconazole 400 mg daily, all three arms in combination with surgery, in patients with eumycetoma in Sudan-pharmacokinetic results

被引：0

作者：

Bruggemann, Roger ^{[1
]}

Nyaoke, Borna ^{[2
]}

Ahmed, Eiman Siddig ^{[3
]}

Siddig, Emanwell Edwar ^{[3
]}

Egondi, Thaddaeus ^{[2
]}

Oyieko, Peelen ^{[2
]}

Bakhiet, Sahar Mubarak ^{[3
]}

Zijlstra, Eduard E. ^{[4
]}

Fahal, Ahmed H. ^{[3
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[2] Drugs Neglected Dis initiat DNDi, Nairobi, Kenya

[3] Mycetoma Res Ctr, Khartoum, Sudan

[4] Drugs Neglected Dis initiat DNDi, Geneva, Switzerland

来源：

MEDICAL MYCOLOGY | 2022年 / 60卷 / SUPP 1期

关键词：

D O I：

10.1093/mmy/myac072.S4.5b

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

S4.5b

引用

页码：16 / 16

页数：1

共 3 条

[1] Two dose levels of once-weekly fosravuconazole versus daily itraconazole in combination with surgery in patients with eumycetoma in Sudan: a randomised, double-blind, phase 2, proof-of-concept superiority trial
Fahal, Ahmed H.
Ahmed, Eiman Siddig
Bakhiet, Sahar Mubarak
Bakhiet, Osama Elhadi
Fahal, Lamis Ahmed
Mohamed, Abubakar Ahmed
Mohamedelamin, El Semani Widaa
Bahar, Mustafa El Nour
Attalla, Hadil Yassir
Siddig, Emmanuel Edwar
Mhmoud, Najwa A.
Musa, Ahmed Mudawi
van de Sande, Wendy W. J.
Scherrer, Bruno
Oyieko, Peelen
Egondi, Thaddaeus W.
Onyango, Kevin
Hata, Katsura
Chu, Wan-Yu
Dorlo, Thomas P. C.
Brueggemann, Roger J.
Nyaoke, Borna A.
Strub-Wourgaft, Nathalie
Zijlstra, Eduard
LANCET INFECTIOUS DISEASES, 2024, 24 (11): : 1254 - 1265
[2] Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor
Tack, Jan
Vladimirov, Borislav
Horny, Ivo
Chong, Chui Fung
Eisner, Jessica
Czerniak, Richard
Takanami, Yohei
NEUROGASTROENTEROLOGY AND MOTILITY, 2023, 35 (01):
[3] PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PROOF OF CONCEPT STUDY OF EFFICACY OF RIFAMYCIN SV-MMX® 600 MG ADMINISTERED THREE OR TWO TIMES DAILY TO PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D)
Balsiger, Lukas M.
Santos, Javier
Serra, Jordi
Piessevaux, Hubert
Baert, Didier
Storr, Martin
Basilisco, Guido
Mazzetti, Alessandro
Moro, Luigi
Gerloni, Mara
Longo, Luigi
Gentili, Alessandra
Tack, Jan F.
GASTROENTEROLOGY, 2024, 166 (05) : S54 - S54

← 1 →